255 related articles for article (PubMed ID: 32931951)
1. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.
Le Saux O; Ray-Coquard I; Labidi-Galy SI
Semin Cancer Biol; 2021 Dec; 77():127-143. PubMed ID: 32931951
[TBL] [Abstract][Full Text] [Related]
2. New approaches for targeting platinum-resistant ovarian cancer.
McMullen M; Madariaga A; Lheureux S
Semin Cancer Biol; 2021 Dec; 77():167-181. PubMed ID: 32871277
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for platinum-resistant ovarian cancer.
Bogani G; Lopez S; Mantiero M; Ducceschi M; Bosio S; Ruisi S; Sarpietro G; Guerrisi R; Brusadelli C; Dell'Acqua A; Di Donato V; Raspagliesi F
Gynecol Oncol; 2020 Aug; 158(2):484-488. PubMed ID: 32518015
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies.
Leung SOA; Konstantinopoulos PA
Expert Opin Investig Drugs; 2021 Jul; 30(7):695-707. PubMed ID: 34082614
[No Abstract] [Full Text] [Related]
8. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Manyam M; Stephens AJ; Kennard JA; LeBlanc J; Ahmad S; Kendrick JE; Holloway RW
Gynecol Oncol; 2021 Dec; 163(3):481-489. PubMed ID: 34686353
[TBL] [Abstract][Full Text] [Related]
9. [Current advances in immunotherapy in ovarian cancer].
Le Saux O; Dubois B; Stern MH; Terme M; Tartour E; Classe JM; Chopin N; Trédan O; Caux C; Ray-Coquard I
Bull Cancer; 2020 Apr; 107(4):465-473. PubMed ID: 32089245
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Mittica G; Genta S; Aglietta M; Valabrega G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27447625
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
14. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
15. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Liu Z; Jing C; Kong F
J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
[TBL] [Abstract][Full Text] [Related]
16. Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA; Reader J; Roque DM
Curr Treat Options Oncol; 2018 Nov; 19(12):74. PubMed ID: 30430276
[TBL] [Abstract][Full Text] [Related]
17. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
18. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Liu JF; Herold C; Gray KP; Penson RT; Horowitz N; Konstantinopoulos PA; Castro CM; Hill SJ; Curtis J; Luo W; Matulonis UA; Cannistra SA; Dizon DS
JAMA Oncol; 2019 Dec; 5(12):1731-1738. PubMed ID: 31600397
[TBL] [Abstract][Full Text] [Related]
20. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]